IACS-010759 (IACS-10759)

製品コードS8731 バッチS873106

印刷

化学情報

Synonyms

N/A

Storage
(From the date of receipt)

3 years -20°C powder

化学式

C₂₅H₂₅F₃N₆O₄S

分子量

562.56

CAS No.

1570496-34-2

Solubility (25°C)*

体外

DMSO

33 mg/mL (58.66 mM)

Water

Insoluble

Ethanol

Insoluble

体内（毎回新しく調製した物を用意してください）

Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O この製剤はselleckのラボで検証済みです。上記の溶解方法がご要望を満たさない場合、selleckの営業担当までお問い合わせ頂ければ、個別の試験を行います。	0.500mg/ml (0.89mM)	Taking the 1 mL working solution as an example, add 50 μL of 10 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

溶剤液（一定の濃度）を調合する

生物活性

製品説明	IACS-010759 (IACS-10759) is a potent and selective oxidative phosphorylation inhibitor (IC50 < 10 nM) that blocks cellular respiration through inhibition of complex I.
in vitro	IACS-010759 (IACS-10759) significantly reduced viability measured by CTG assay in all cell lines tested (Notch mutant: Pf382, 1301, Jurkat, MOLT-4, P12-Ichikawa and Notch wt: T-ALL1). Treatment of T-ALL with this compound effectively inhibited FA-stimulated mitochondrial respiration indicated by decreased oxygen consumption rates (OCR). However, the cells maintain an ability to generate energy via glycolysis, indicated by high extracellular acidification rate (ECAR) in both, control and IACS-treated groups^[1]. In CLL cells, it causes minimal cell death, inhibits oxygen consumption rate (OCR) and increases glycolysis. It also decreases intracellular ribonucleotide triphosphate pools in CLL^[2]. In sensitive AML cells, the compound induces AMPK activation leading to mTOR suppression which results in cell growth inhibition in AML cells. AMPK and mTOR could be putative biomarkers of anti-leukemia activity of the novel OxPhos inhibitor IACS-010759^[3].
in vivo	IACS-010759 (IACS-10759) is a potent inhibitor of mitochondria complex I of the electron transport chain. It inhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on oxidative phosphorylation.^[4]

製品説明

IACS-010759 (IACS-10759) is a potent and selective oxidative phosphorylation inhibitor (IC50 < 10 nM) that blocks cellular respiration through inhibition of complex I.

in vitro

IACS-010759 (IACS-10759) significantly reduced viability measured by CTG assay in all cell lines tested (Notch mutant: Pf382, 1301, Jurkat, MOLT-4, P12-Ichikawa and Notch wt: T-ALL1). Treatment of T-ALL with this compound effectively inhibited FA-stimulated mitochondrial respiration indicated by decreased oxygen consumption rates (OCR). However, the cells maintain an ability to generate energy via glycolysis, indicated by high extracellular acidification rate (ECAR) in both, control and IACS-treated groups^[1].

In CLL cells, it causes minimal cell death, inhibits oxygen consumption rate (OCR) and increases glycolysis. It also decreases intracellular ribonucleotide triphosphate pools in CLL^[2].

In sensitive AML cells, the compound induces AMPK activation leading to mTOR suppression which results in cell growth inhibition in AML cells. AMPK and mTOR could be putative biomarkers of anti-leukemia activity of the novel OxPhos inhibitor IACS-010759^[3].

in vivo

IACS-010759 (IACS-10759) is a potent inhibitor of mitochondria complex I of the electron transport chain. It inhibits proliferation and induces apoptosis in models of brain cancer and acute myeloid leukemia (AML) reliant on oxidative phosphorylation.^[4]

プロトコル(参考用のみ)

細胞アッセイ	細胞株	CLL cells
	濃度	30 nM, 100 nM, 300 nM, 1 μM, and 3 μM
	反応時間	24 or 48 h
	実験の流れ	After treatment with IACS-010759 (IACS-10759) for 24 or 48 h, CLL cells were stained with acridine orange and analyzed by flow cytometry.
動物実験	動物モデル	Male SD rats
	投薬量	0.3 mg/kg
	投与方法	i.v.

参考

http://www.bloodjournal.org/content/128/22/4028?sso-checked=true
https://pubmed.ncbi.nlm.nih.gov/29861847/
http://www.bloodjournal.org/content/130/Suppl_1/1245

https://pubmed.ncbi.nlm.nih.gov/29892070/

+ 展开

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

Inhibition of heme biosynthesis triggers cuproptosis in acute myeloid leukemia [ Cell, 2025, S0092-8674(25)01233-4]	PubMed: 41265435
OASL enhances mRNA translation and reprograms lipid metabolism to promote cancer progression [ Cell Rep, 2025, 44(7):115901]	PubMed: 40608514
Metabolic adaptations to acute glucose uptake inhibition converge upon mitochondrial respiration for leukemia cell survival [ Cell Commun Signal, 2025, 23(1):47]	PubMed: 39863913
Complex I inhibition combined with TLR activation in the breast tumor microenvironment educates cytotoxic neutrophils [ Sci Adv, 2025, 11(28):eadu5915]	PubMed: 40644540
Protocol for real-time measurement of mitochondrial bioenergetics in 3D-cultured brain tumor stem cells using the Resipher system [ STAR Protoc, 2025, 6(1):103651]	PubMed: 39998952
A simple liquid 3D cell culture paradigm models oxidative mitochondrial metabolism of epithelial breast cancer cells with relevance for lung metastases [ bioRxiv, 2025, 2025.08.24.671623]	PubMed: 40909564
Mitochondrial complex I promotes kidney cancer metastasis [ Nature, 2024, 10.1038/s41586-024-07812-3]	PubMed: 39143213
Compensatory activity of the PC-ME1 metabolic axis underlies differential sensitivity to mitochondrial complex I inhibition [ Nat Commun, 2024, 15(1):8682]	PubMed: 39375345
Self-renewing human naïve pluripotent stem cells dedifferentiate in 3D culture and form blastoids spontaneously [ Nat Commun, 2024, 15(1):668]	PubMed: 38253551
Respiratory complex I regulates dendritic cell maturation in explant model of human tumor immune microenvironment [ J Immunother Cancer, 2024, 12(4)e008053]	PubMed: 38604809

長期の保管のために-20°Cの下で製品を保ってください。

人間や獣医の診断であるか治療的な使用のためにでない。

各々の製品のための特定の保管と取扱い情報は、製品データシートの上で示されます。大部分のSelleck製品は、推薦された状況の下で安定です。製品は、推薦された保管温度と異なる温度で、時々出荷されます。長期の保管のために必要とされてそれと異なる温度で、多くの製品は、短期もので安定です。品質を維持するが、夜通しの積荷のために最も経済的な貯蔵状況を用いてあなたの送料を保存する状況の下に、製品が出荷されることを、我々は確実とします。製品の受領と同時に、製品データシートの上で貯蔵推薦に従ってください。